2. Search Result
Search Result
Results for "

hypothalamus

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

18

Peptides

4

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1811
    Vasopressin
    Maximum Cited Publications
    12 Publications Verification

    		 Endogenous Metabolite Neurological Disease
    Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .
    Vasopressin
  • HY-P3561A
    Agouti-related Protein (AGRP) (83-132) Amide (human) (TFA)

    		Melanocortin Receptor Neurological Disease
    Agouti-related Protein (AGRP) (83-132) Amide (human) TFA is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
    Agouti-related Protein (AGRP) (83-132) Amide (human) (TFA)
  • HY-P0243
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon

    Salmon GnRH; Salmon gonadotropin-releasing hormone; sGnRH

    		 GnRH Receptor Metabolic Disease
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon (Salmon GnRH) is the hypophysiotropic decapeptide synthesized in the hypothalamus that plays a crucial role in the control of reproductive functions.
    Luteinizing Hormone Releasing Hormone (LH-RH), salmon
  • HY-P1025A
    M40 TFA

    		Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    M40 TFA is the TFA salt form of M40. M40 TFA is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas .
    M40 TFA
  • HY-P3561
    Agouti-related Protein (AGRP) (83-132) Amide (human)

    		Melanocortin Receptor Neurological Disease
    Agouti-related Protein (AGRP) (83-132) Amide (human) is a fragment of agouti-related protein (AGRP) which is a protein found in abundance in the arcuate nucleus of the hypothalamus. AgRP primarily acts as an inverse agonist for the melanocortin-4 receptor (MC4R) to increase food intake .
    Agouti-related Protein (AGRP) (83-132) Amide (human)
  • HY-P3604
    LH-RH II (chicken)

    		Androgen Receptor Endocrinology
    LH-RH II (chicken) is one of the two forms of luteinizing hormone-releasing hormone (LHRH) the hypothalamus of the domestic hen, which are structural variants of mammalian LHRH. LH-RH II (chicken) enhances gonadotrophin release in the domestic chicken .
    LH-RH II (chicken)
  • HY-135242
    LY87130 free base

    		Others Endocrinology
    LY87130 free base is an octopamine-N-methyltransferase inhibitor with epinephrine-inhibiting activity. LY87130 free base can significantly reduce the basal level of epinephrine in the hypothalamus after administration. LY87130 free base has no significant effect on the basal levels of norepinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) in the hypothalamus .
    LY87130 free base
  • HY-P1025
    M40

    		Neuropeptide Y Receptor Cardiovascular Disease Neurological Disease
    M40 is an antagonist or a weak agonist for galanin receptor depending on different subtypes of galanin receptors in the brain, hypothalamus, hippocampus, amygdala and pancreas .
    M40
  • HY-P3675
    LH-RH (4-10)

    		GnRH Receptor Endocrinology
    LH-RH (4-10) is a heptapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (4-10) produced in macrophages and type II pneumocytes .
    LH-RH (4-10)
  • HY-103560
    (S)-HexylHIBO

    		mGluR Neurological Disease
    (S)-HexylHIBO is the S-enantiomer of HexylHIBO. HexylHIBO is a group I mGluR antagonist. HexylHIBO elevates the hypothalamus-pituitary-adrenal axis response to restraint in rats. HexylHIBO is promising for research of central nervous system-related diseases .
    (S)-HexylHIBO
  • HY-P3674
    LH-RH (7-10)

    		GnRH Receptor Endocrinology
    LH-RH (7-10) is a tetrapeptide, one of major degradation products of luteinising-hormone releasing hormone (LHRH) via pituitary and hypothalamus. LH-RH (7-10) produced in macrophages, type I-like and type II pneumocytes .
    LH-RH (7-10)
  • HY-P1502
    β-Endorphin, human
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
    β-Endorphin, human
  • HY-115447
    Clobenpropit

    		Histamine Receptor Neurological Disease
    Clobenpropit is a potent histamine H3-receptor antagonist. Clobenpropit decreases dopamine release and increases histamine levels in the hypothalamus. Clobenpropit shows antipsychotic-like activities. Clobenpropit causes a resuscitating effect in rats subjected to the hemorrhagic shock .
    Clobenpropit
  • HY-P5064
    Galanin-Like Peptide (porcine)

    		Neuropeptide Y Receptor Neurological Disease
    Galanin-Like Peptide (porcine) is a 60 amino acid neuropeptide that was first isolated from the porcine hypothalamus. Galanin-Like Peptide (porcine) has a high affinity for the GALR2 receptor (IC50 of 0.24 nM) and a lower affinity for the GALR1 receptor (IC50 of 4.3 nM) .
    Galanin-Like Peptide (porcine)
  • HY-B0451
    Dopamine
    5+ Cited Publications

    ASL279 free base

    		 Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine plays several important roles in the brain and body . Dopamine acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Dopamine
  • HY-B0451A
    Dopamine hydrochloride
    5+ Cited Publications

    ASL279

    		 Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Dopamine hydrochloride
  • HY-107761
    JMV 390-1

    		Others Neurological Disease
    JMV 390-1 (Compound 6a) is a potent multipeptidase inhibitor. JMV 390-1 behaves as a full inhibitor of the major neurotensin (NT)/neuromedin N (NN) degrading enzymes in vitro with IC50 values from 30 to 60 nM. JMV 390-1 increases endogenous recovery of NT and NN from slices of mice hypothalamus depolarized with potassium .
    JMV 390-1
  • HY-N12634
    Pregnant mare serum gonadotropin

    PMSG

    		 Endogenous Metabolite Endocrinology
    Pregnant mare serum gonadotropin (PMSG) is a gonadotropin used to promote follicular development and ovulation in animals. PMSG exerts its regulatory effects by stimulating changes in blood hormones, gonadotropins, and cytoplasmic estradiol receptors in the anterior pituitary and hypothalamus. PMSG is commonly used in livestock to improve reproductive efficiency and can also be utilized for research on estrous cycle regulation .
    Pregnant mare serum gonadotropin
  • HY-14450
    JNJ-31020028
    1 Publications Verification

    		 Neuropeptide Y Receptor Neurological Disease Endocrinology
    JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease .
    JNJ-31020028
  • HY-119409
    Levophacetoperane

    Phacetoperane free base

    		 Dopamine Transporter Neurological Disease
    Levophacetoperane (Phacetoperane free base) competitively inhibits the uptake of norepinephrin and dopamine .
    Levophacetoperane
  • HY-B1811S1
    Vasopressin-d5

    		Isotope-Labeled Compounds Others
    Vasopressin-d5 is anIsotope-labeled compound of Vasopressin. Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of the corticotropin-releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors .
    Vasopressin-d5
  • HY-B0451AS7
    Dopamine-d5 hydrochloride

    		Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine-d5 (hydrochloride) is the deuterium labeled Dopamine (hydrochloride). Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body[1]. Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis[1].
    Dopamine-d5 hydrochloride
  • HY-17610
    Enerisant

    TS-091

    		 Histamine Receptor Neurological Disease
    Enerisant is a potent, highly selective, competitive and orally active histamine H3 receptor antagonist/inverse agonist with IC50s of 2.89 nM and 14.5 nM against human and rat histamine H3 receptors, respectively .
    Enerisant
  • HY-17610A
    Enerisant hydrochloride

    TS-091 hydrochloride

    		 Histamine Receptor Neurological Disease
    Enerisant (TS-091) hydrochloride is a potent, highly selective, competitive and orally active histamine H3 receptor antagonist/inverse agonist with IC50s of 2.89 nM and 14.5 nM against human and rat histamine H3 receptors, respectively .
    Enerisant hydrochloride
  • HY-P10289
    Neuropeptide W-30 (rat)

    NPW30, rat

    		 Neuropeptide B/W Receptor Neurological Disease
    Neuropeptide W-30 (rat) is an important stress mediator in the central nervous system that modulates the hypothalamus-pituitary-adrenal (HPA) axis and sympathetic outflow. Neuropeptide W-30 (rat) is an endogenous ligand for the two structurally related orphan G-protein-coupled receptors (GPCRs) GPR7 and GPR8. NPW-30 activates and binds to both GPR7 and GPR8 at similar effective doses .
    Neuropeptide W-30 (rat)
  • HY-P10287
    Neuropeptide W-30 (human)

    NPW30, human

    		 Neuropeptide B/W Receptor Neurological Disease
    Neuropeptide W-30 (human) is an important stress mediator in the central nervous system that modulates the hypothalamus-pituitary-adrenal (HPA) axis and sympathetic outflow. Neuropeptide W-30 (human) is an endogenous ligand for the two structurally related orphan G-protein-coupled receptors (GPCRs) GPR7 and GPR8. Neuropeptide W-30 (human) activates and binds to both GPR7 and GPR8 at similar effective doses .
    Neuropeptide W-30 (human)
  • HY-P0262
    Galantide

    		Neuropeptide Y Receptor Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (KD<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC50=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (KD~40 nM) .
    Galantide
  • HY-P2161
    TAK-683

    		Kisspeptin Receptor Cancer
    TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683
  • HY-P2161B
    TAK-683 acetate
    1 Publications Verification

    		 Kisspeptin Receptor Cancer
    TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 acetate
  • HY-P2161A
    TAK-683 TFA

    		Kisspeptin Receptor Cancer
    TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 TFA
  • HY-136625
    LY134046

    		Others Neurological Disease
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT). Its cardiovascular activity was studied in anesthetized spontaneously hypertensive rats (SHR). Acute intraperitoneal injection of 10 and 20 mg/kg of LY134046 caused minimal cardiovascular changes, while 40 mg/kg resulted in a sustained decrease in mean arterial blood pressure and heart rate. This hypotension and bradycardia occurred rapidly and occurred when brain NMT activity was significantly inhibited. However, norepinephrine concentrations in rat brains were not significantly reduced at the time when LY134046-induced blood pressure and heart rate effects were maximal. The acute cardiovascular activity of LY134046 was not significantly affected by pretreatment of SHR with phentolamine, propranolol, or atropine, and LY134046 reduced heart rate in suspended SHR. In addition, acute or chronic administration of LY134046 did not antagonize the vasoconstrictor responses induced by sympathetic nerve stimulation or exogenous norepinephrine. These observations suggest that LY134046 does not interact with adrenergic or cholinergic receptors and that its hypotensive and bradycardic effects do not require neurogenic tension. Chronic intraperitoneal administration of LY134046 (40 mg/kg/day) resulted in a sustained and significant inhibition of hypothalamic and brainstem NMT activity, leading to central norepinephrine depletion. During chronic treatment, norepinephrine and dopamine concentrations increased in the brainstem and hypothalamus of SHR. Despite chronic inhibition of central NMT and norepinephrine depletion, cardiovascular parameters in SHR treated groups were not significantly different from those in saline-injected controls. Chronic treatment with LY134046 did not result in tolerance to its central biochemical effects or acute cardiovascular activity. The present study does not support the idea that norepinephrine-producing neurons are involved in the central regulation of cardiovascular function, because the hypotension and bradycardia induced by acute administration of LY134046 occurred before a significant decrease in hypothalamic norepinephrine concentrations, whereas chronic inhibition of central NMT and depletion of norepinephrine resulted in minimal changes in baseline cardiovascular parameters.
    LY134046

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: